Advertisement

Topics

Merus Receives Milestone Payment from Ono Pharmaceutical for Selection of Bispecific Antibody Candidate for Clinical Development and Extends Partnership with CMC Service Agreement

09:00 EDT 19 Oct 2016 | GlobalNewsWire (2014)
This article has expired, however you can still download the PDF.
Preview:
UTRECHT, The Netherlands, Oct. 19, 2016 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced that the Company received an undisclosed mi...

Other Sources for this Article

NEXT ARTICLE

More From BioPortfolio on "Merus Receives Milestone Payment from Ono Pharmaceutical for Selection of Bispecific Antibody Candidate for Clinical Development and Extends Partnership with CMC Service Agreement"

Quick Search
Advertisement
 

Relevant Topics

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...